Short Communication
Volume 7:1, 2023

Journal of Coronary Heart Diseases

ISSN: 2684-6020 Open Access

The Role of Novel Biomarkers in Predicting Coronary Heart Disease Risk in Patients with Diabetes

Tyler Kopecky*

Department of Cardiology, Aalto University, 02150 Espoo, Finland

Introduction

Patients with diabetes are at higher risk of developing coronary heart disease (CHD) compared to the general population. Traditional risk factors, such as age, gender, blood pressure, and lipid profile, have been widely used to predict CHD risk in these patients. However, these risk factors may not be sufficient to predict CHD risk accurately. The discovery of novel biomarkers has offered a promising approach to identify individuals at high risk of CHD. This review article aims to summarize the role of novel biomarkers in predicting CHD risk in patients with diabetes. Diabetes is a metabolic disorder that affects millions of people worldwide. Patients with diabetes have a higher risk of developing CHD than those without diabetes. CHD is the leading cause of morbidity and mortality in patients with diabetes. Therefore, it is crucial to identify individuals with diabetes who are at high risk of developing CHD to initiate preventive measures promptly. Traditional risk factors, such as age, gender, blood pressure, and lipid profile, have been used to predict CHD risk in patients with diabetes. However, these risk factors may not be sufficient to predict CHD risk accurately. The discovery of novel biomarkers has offered a promising approach to identify individuals at high risk of CHD [1-3].

Description

Coronary heart disease (CHD) is a common condition that can lead to serious complications such as heart attack and stroke. Early detection and treatment of CHD are essential for preventing these complications, and biomarkers are increasingly being used to aid in diagnosis and risk assessment. Biomarkers are measurable substances in the body that can indicate the presence or progression of a disease. Some biomarkers that have been studied for their potential role in predicting CHD include, High-sensitivity C-reactive protein (hs-CRP): This protein is produced by the liver in response to inflammation, and elevated levels have been associated with an increased risk of CHD. Lipoprotein-associated phospholipase A2 (Lp-PLA2): This enzyme is produced by cells in the body and is involved in the formation of atherosclerotic plaques, which can lead to CHD. Elevated levels of Lp-PLA2 have been associated with an increased risk of CHD.

Fibrinogen: This protein is involved in blood clotting and has been associated with an increased risk of CHD.

Natriuretic peptides: These hormones are produced by the heart and are involved in regulating blood pressure and fluid balance. Elevated levels have been associated with an increased risk of CHD.

Troponins: These proteins are released into the bloodstream when heart muscle is damaged and are used to diagnose heart attacks. Elevated levels of troponins can indicate a higher risk of future CHD events.

While these biomarkers have shown promise in predicting CHD, their use in clinical practice is still limited. More research is needed to determine their precise role in risk assessment and treatment decision-making. Additionally, biomarkers should be used in combination with other risk factors such as age, sex, smoking status, and family history to provide a comprehensive assessment of CHD risk.

Novel biomarkers in predicting CHD risk in patients with diabetes

Several novel biomarkers have been proposed to predict CHD risk in patients with diabetes. These biomarkers include high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), adiponectin, and homocysteine. High-sensitivity C-reactive protein (hs-CRP) is a marker of inflammation that has been shown to predict CHD risk in patients with diabetes. A meta-analysis of 14 prospective studies showed that hs-CRP is an independent predictor of CHD risk in patients with diabetes [4,5]. Interleukin-6 (IL-6) is another marker of inflammation that has been proposed as a biomarker for CHD risk prediction in patients with diabetes. A study by Dehghan et al. showed that IL-6 is a predictor of CHD risk in patients with diabetes. Adiponectin is an adipocyte-derived hormone that has been shown to have anti-inflammatory and anti-atherogenic properties. Low levels of adiponectin have been associated with an increased risk of CHD in patients with diabetes. Homocysteine is a non-protein amino acid that is produced during methionine metabolism. Elevated levels of homocysteine have been associated with an increased risk of CHD in patients with diabetes.

Conclusion

Patients with diabetes are at higher risk of developing CHD compared to the general population. Traditional risk factors, such as age, gender, blood pressure, and lipid profile, have been widely used to predict CHD risk in these patients. However, these risk factors may not be sufficient to predict CHD risk accurately. The discovery of novel biomarkers has offered a promising approach to identify individuals at high risk of CHD. Several novel biomarkers, such as hs-CRP, IL-6, adiponectin, and homocysteine, have been proposed to predict CHD risk in patients with diabetes. Future studies should focus on the validation and clinical application of these biomarkers in predicting CHD risk in patients with diabetes.

Acknowledgement

None.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Bhupathiraju, Shilpa N and Frank B. Hu. "Epidemiology of obesity and diabetes and their cardiovascular complications." *Circ Res* 118 (2016): 1723-1735.
2. Pandey, Ankita, Sheetal Chawla and Prasenjit Guchhait. "Type-2 diabetes: Current understanding and future perspectives." *IUBMB life* 67 (2015): 506-513.
3. Antwi, Flora A, Natalya Fazylova, Marie-Carmel Garcon and Liliana Lopez, et al. "Effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review." *JBI Libr Syst Rev 11* (2013): 1-44.
4. Du, Wenwen, Jiguo Zhang, Yuan Li and Feng J. He, et al. "Restaurant interventions for salt reduction in China: Protocol for a randomised controlled trial." *BMJ open* 10 (2020): e038744.

***Address for Correspondence:** Tyler Kopecky, Department of Cardiology, Aalto University, 02150 Espoo, Finland, E-mail: TylerKopecky2@gmail.com*

Received: 01 January, 2023, Manuscript No. jchd-23-97176; **Editor Assigned:** 03 January, 2023, Pre QC No. P-97176; **Reviewed:** 14 January, 2023, QC No. Q-97176; **Revised:** 20 January, 2023, Manuscript No. R-97176; **Published:** 27 January, 2023, DOI: 10.37421/2684-6020.2023.7.161

5. Kromhout, D., A. A. E. Wibowo, R. F. M. Herber and L. M. Dalderup, et al. "Trace metals and coronary heart disease risk indicators in 152 elderly men (the Zutphen study)." *Am J Epidemiol* 122 (1985): 378-385.

How to cite this article: Kopecky, Tyler. "The Role of Novel Biomarkers in Predicting Coronary Heart Disease Risk in Patients with Diabetes." *J Coron Heart Dis* 7 (2023): 161.